Alnylam Pharmaceuticals initiates dosing in Phase I human clinical study with ALN-TTR01 Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, announced today it has initiated dosing in a Stage I human clinical research with ALN-TTR01. The study is aimed at evaluating the protection and tolerability of ALN-TTR01 in individuals with transthyretin -mediated amyloidosis , and can be designed to offer preliminary data on human being proof concept based on measurements of TTR serum levels.The nursing and medical personnel must all be board certified and there should be a licensed physician acting as the medical director. It should be open seven days a week. The service must contain multiple examination house and rooms on-site medical, diagnostic tools like x-ray machines and also have a well outfitted phlebotomy department. Each care centre must adhere to a standardized set of ethics and business practices also. Urgent care centres have to be well maintained and run like a business to be able to remain a secured asset to the various communities and people they service.